Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan

W. L. Ho, K. H. Lin, J. D. Wang, J. S. Hwang, C. W. Chung, D. T. Lin, S. T. Jou, M. Y. Lu, J. P.S. Chern

研究成果: Article同行評審

30 引文 斯高帕斯(Scopus)

摘要

The thalassemias are a heterogeneous group of inherited hypochromic anemias of varying severity. The mainstay of supportive treatment is regular blood transfusion accompanied by iron-chelating therapy. Hematopoietic stem cell transplantation (HSCT) provides an alternative option when curative therapy is considered. More than 400 patients in Taiwan have β-thalassemia major or other transfusion-dependent thalassemias, and their treatment costs account for a considerable percentage of the National Health Insurance expenditure. In this report, we estimated the treatment costs of conventional therapy (regular blood transfusion accompanied by iron-chelating agents) and HSCT. The undiscounted medical cost of 20 years of follow-up (20 years from diagnosis) and the undiscounted total lifetime cost were NT$ 4739888 (NT$ means New Taiwan Dollars)/US$ 149288 and NT$ 11529990/US$ 363149, respectively, for patients undergoing conventional therapy, and NT$ 2639982/US$ 83149 and NT$ 3511172/US$ 110588, respectively, for those undergoing successful HSCT. Comparisons of treatment costs and other parameters between these two modalities can add to the information base on which policy is made by health authorities or clinicians.

原文English
頁(從 - 到)569-574
頁數6
期刊Bone Marrow Transplantation
37
發行號6
DOIs
出版狀態Published - 2006 3月

All Science Journal Classification (ASJC) codes

  • 血液學
  • 移植

指紋

深入研究「Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan」主題。共同形成了獨特的指紋。

引用此